NIKI — Niki BioSolutions, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1734005 ·
Last close
$1.50
Market Cap
$4.41M
52W High
$17.20
52W Low
$1.41
ADV30
20,363
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -825,131 | -307,495 | 18,691,370 | 3,452,891 | 4,899,823 |
| Sep 2025 | 0 | — | -589,631 | -613,995 | 17,578,751 | 2,272,611 | 4,416,347 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,020,002
Investing CF
$0
Financing CF
$1,715,999
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-10-25
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,792,798
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-1,414,762
Pretax Income TTM
$-927,135
Interest Exp TTM
$26,964
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,817,528 | -1,363,270 | 18,691,370 | 4,899,823 | 23,162,160 | -1,836,546 |
| Dec 2024 | 0 | -3,002,298 | -4,267,806 | 16,130,223 | 4,353,162 | 21,134,514 | -1,189,734 |
| Dec 2023 | 431,378 | -10,601,236 | -2,824,647 | 20,640,091 | 5,256,738 | 24,846,236 | -7,724,364 |
| Dec 2022 | 1,295,889 | -17,173,614 | -9,799,560 | 20,867,371 | 13,034,066 | 15,712,094 | -12,318,965 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SFHG | SAMFINE CREATION HOLDINGS GROUP Ltd | $4.41M | $1.95 | — |
| INUV | Inuvo, Inc. | $4.39M | $0.27 | — |
| EXCBF | Excalibur Metals Corp. | $4.39M | $0.07 | — |
| PRPL | Purple Innovation, Inc. | $4.36M | $1.00 | — |
| FCUV | FOCUS UNIVERSAL INC. | $4.50M | $4.58 | — |
News headlines (Yahoo Finance, 1h cache)
Niki BioSolutions Announces Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 Conference
2026-11-09 16:40 · Yahoo
Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine
2026-10-26 13:15 · Yahoo
Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research
2026-10-23 12:00 · Yahoo
Niki BioSolutions’ Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation’s “Rett Research Tool Belt” Series
2026-10-16 12:00 · Yahoo
Niki BioSolutions Partners with Global Alzheimer’s Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002
2026-10-14 12:00 · Yahoo
Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics
2026-09-14 12:30 · Yahoo
Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Niki BioSolutions Enters into Strategic Agreement to Provide APOE Testing Services for Progressive Medical Research (PMR)
2026-07-23 12:00 · Yahoo
Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference
2026-09-25 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.